HK1178910A1 - 用於治療癌症的人源化抗 抗體 - Google Patents
用於治療癌症的人源化抗 抗體Info
- Publication number
- HK1178910A1 HK1178910A1 HK13105830.8A HK13105830A HK1178910A1 HK 1178910 A1 HK1178910 A1 HK 1178910A1 HK 13105830 A HK13105830 A HK 13105830A HK 1178910 A1 HK1178910 A1 HK 1178910A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cxcr4
- treatment
- cancer
- humanized anti
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- AIDS & HIV (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Radiology & Medical Imaging (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10290167A EP2371863A1 (en) | 2010-03-30 | 2010-03-30 | Humanized anti CXCR4 antibodies for the treatment of cancer |
US12/749,891 US8557964B2 (en) | 2008-10-01 | 2010-03-30 | Anti CXCR4 antibodies and their use for the treatment of cancer |
PCT/EP2011/054945 WO2011121040A1 (en) | 2010-03-30 | 2011-03-30 | Humanized anti cxcr4 antibodies for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1178910A1 true HK1178910A1 (zh) | 2013-09-19 |
Family
ID=42556901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13105830.8A HK1178910A1 (zh) | 2010-03-30 | 2013-05-16 | 用於治療癌症的人源化抗 抗體 |
Country Status (30)
Country | Link |
---|---|
US (1) | US9249223B2 (zh) |
EP (2) | EP2371863A1 (zh) |
JP (1) | JP5749330B2 (zh) |
KR (1) | KR101838310B1 (zh) |
CN (1) | CN102939306B (zh) |
AR (1) | AR080740A1 (zh) |
AU (1) | AU2011234458B2 (zh) |
CA (1) | CA2794407C (zh) |
CL (1) | CL2012002700A1 (zh) |
CO (1) | CO6571881A2 (zh) |
CY (1) | CY1115349T1 (zh) |
DK (1) | DK2552963T3 (zh) |
ES (1) | ES2469369T3 (zh) |
HK (1) | HK1178910A1 (zh) |
HR (1) | HRP20140502T1 (zh) |
IL (1) | IL222198A (zh) |
MA (1) | MA34175B1 (zh) |
MX (1) | MX2012011206A (zh) |
NZ (1) | NZ603182A (zh) |
PL (1) | PL2552963T3 (zh) |
PT (1) | PT2552963E (zh) |
RS (1) | RS53405B (zh) |
RU (1) | RU2595394C2 (zh) |
SG (1) | SG184308A1 (zh) |
SI (1) | SI2552963T1 (zh) |
TN (1) | TN2012000466A1 (zh) |
TW (1) | TWI549689B (zh) |
UA (1) | UA106529C2 (zh) |
WO (1) | WO2011121040A1 (zh) |
ZA (1) | ZA201208015B (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
JP2014504147A (ja) * | 2010-10-27 | 2014-02-20 | ピエール、ファーブル、メディカマン | Hivの治療用抗体 |
US20140120555A1 (en) * | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
EP2723380B1 (en) | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
KR101809072B1 (ko) * | 2013-08-02 | 2017-12-14 | 화이자 인코포레이티드 | 항-cxcr4 항체 및 항체-약물 접합체 |
AU2017206785C1 (en) * | 2016-01-13 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Rodents having an engineered heavy chain diversity region |
TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
WO2019191133A1 (en) | 2018-03-27 | 2019-10-03 | Bristol-Myers Squibb Company | Real-time monitoring of protein concentration using ultraviolet signal |
WO2020172658A1 (en) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Methods of isolating a protein |
CN114245869A (zh) | 2019-05-23 | 2022-03-25 | 百时美施贵宝公司 | 监测细胞培养基的方法 |
US20230374064A1 (en) | 2020-10-05 | 2023-11-23 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
EP4005923B1 (de) | 2020-11-30 | 2023-08-30 | Bucher Leichtbau AG | Bordverpflegungsstation |
WO2023173011A1 (en) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
MXPA06000252A (es) * | 2003-06-30 | 2006-12-15 | Bio Technology General Israel | Anticuerpos y usos de los mismos. |
BRPI0718197A2 (pt) * | 2006-10-02 | 2014-09-30 | Medarex Inc | Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, e, métodos para preparar um anticorpo anti-cxcr4, para modular a atividade do cxcr4 em uma célula, e para estimular a mobilização de células tronco cd34+ da medula óssea para o sangue periférico em um indivíduo. |
FR2907341B1 (fr) * | 2006-10-18 | 2012-08-17 | Pf Medicament | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer |
UY30838A1 (es) * | 2006-12-26 | 2008-07-31 | Centro Inmunologia Molecular | Composicion farmacéutica que comprende un anticuerpo monoclonal anti cd6 utilizado en el diagnostico y tratamiento de la artritis reumatoide |
JP2011520885A (ja) * | 2008-05-14 | 2011-07-21 | イーライ リリー アンド カンパニー | 抗cxcr4抗体 |
EP2285833B1 (en) * | 2008-05-16 | 2014-12-17 | Ablynx N.V. | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
EP2172485A1 (en) * | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
-
2010
- 2010-03-30 EP EP10290167A patent/EP2371863A1/en not_active Withdrawn
-
2011
- 2011-03-29 TW TW100110752A patent/TWI549689B/zh not_active IP Right Cessation
- 2011-03-30 MA MA35329A patent/MA34175B1/fr unknown
- 2011-03-30 NZ NZ603182A patent/NZ603182A/en not_active IP Right Cessation
- 2011-03-30 CA CA2794407A patent/CA2794407C/en not_active Expired - Fee Related
- 2011-03-30 US US13/637,198 patent/US9249223B2/en not_active Expired - Fee Related
- 2011-03-30 KR KR1020127028361A patent/KR101838310B1/ko active IP Right Grant
- 2011-03-30 MX MX2012011206A patent/MX2012011206A/es active IP Right Grant
- 2011-03-30 SG SG2012071882A patent/SG184308A1/en unknown
- 2011-03-30 DK DK11711554.3T patent/DK2552963T3/da active
- 2011-03-30 EP EP11711554.3A patent/EP2552963B1/en not_active Not-in-force
- 2011-03-30 RS RS20140343A patent/RS53405B/en unknown
- 2011-03-30 RU RU2012145232/10A patent/RU2595394C2/ru not_active IP Right Cessation
- 2011-03-30 CN CN201180024677.3A patent/CN102939306B/zh not_active Expired - Fee Related
- 2011-03-30 PT PT117115543T patent/PT2552963E/pt unknown
- 2011-03-30 AU AU2011234458A patent/AU2011234458B2/en not_active Ceased
- 2011-03-30 ES ES11711554.3T patent/ES2469369T3/es active Active
- 2011-03-30 AR ARP110101043A patent/AR080740A1/es unknown
- 2011-03-30 UA UAA201212273A patent/UA106529C2/uk unknown
- 2011-03-30 JP JP2013501835A patent/JP5749330B2/ja not_active Expired - Fee Related
- 2011-03-30 SI SI201130181T patent/SI2552963T1/sl unknown
- 2011-03-30 PL PL11711554T patent/PL2552963T3/pl unknown
- 2011-03-30 WO PCT/EP2011/054945 patent/WO2011121040A1/en active Application Filing
-
2012
- 2012-04-04 ZA ZA2012/08015A patent/ZA201208015B/en unknown
- 2012-09-26 TN TNP2012000466A patent/TN2012000466A1/en unknown
- 2012-09-27 CL CL2012002700A patent/CL2012002700A1/es unknown
- 2012-09-27 IL IL222198A patent/IL222198A/en not_active IP Right Cessation
- 2012-10-30 CO CO12195608A patent/CO6571881A2/es active IP Right Grant
-
2013
- 2013-05-16 HK HK13105830.8A patent/HK1178910A1/zh not_active IP Right Cessation
-
2014
- 2014-06-02 HR HRP20140502AT patent/HRP20140502T1/hr unknown
- 2014-06-11 CY CY20141100422T patent/CY1115349T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1178910A1 (zh) | 用於治療癌症的人源化抗 抗體 | |
IL228738A0 (en) | Antibodies for cancer treatment | |
HK1199099A1 (zh) | 用於治療和診斷癌症的方法和組合物 | |
HK1254859A1 (zh) | 治療乳腺癌的方法 | |
HK1183866A1 (zh) | 治療癌症和免疫與自身免疫疾病的細胞程序死亡誘導藥劑 | |
PL2482849T3 (pl) | Skojarzona immunoterapia w leczeniu nowotworu | |
HK1182593A1 (zh) | 用於治療癌症以及免疫與自身免疫疾病的細胞凋亡誘導劑 | |
HUE047006T2 (hu) | Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére | |
HK1179614A1 (zh) | 用於治療癌症和免疫以及自身免疫性疾病的細胞凋亡誘導劑 | |
HK1165813A1 (zh) | 用於治療 的抗 抗體 | |
EP2688594A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
PT2550296T (pt) | Anticorpos monoclonais para tratamento do cancro | |
TWI561521B (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
EP2723924A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER | |
EP2651443A4 (en) | ANTI-CCL25 AND ANTI-CCR9 ANTIBODIES FOR THE PREVENTION AND TREATMENT OF CANCER AND THE MIGRATION OF CANCER CELLS | |
HK1185874A1 (zh) | 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺 | |
EP2670435A4 (en) | USE OF ANTI-DKK1 MONOCLONAL ANTIBODY FOR THE TREATMENT OF LIVER CANCER | |
HRP20181212T1 (hr) | Anti-alfa-v integrinsko protutijelo za liječenje raka prostate | |
IL223290A (en) | Anti-1α-il antibodies for the treatment of arthritis | |
EP2938633A4 (en) | HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE FOR THE DIAGNOSIS AND TREATMENT OF COLON CANCER AND PANCREATIC CANCER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190401 |